Goldman Sachs Upgrades BioNTech (BNTX) to Buy, 'at the nexus of these significant developments occurring in the oncology field'
Tweet Send to a Friend
Goldman Sachs analyst Asad Haider upgraded BioNTech (NASDAQ: BNTX) from Neutral to Buy with a price target of $142.00 (from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
